WP1066 disrupts janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells

Cancer Research

Volumn 67, Issue 23, 2007, Pages 11291-11299

  Ferrajoli, Alessandra ^a   Faderl, Stefan ^a   Van, Quin ^a   Koch, Patricia ^a   Harris, David ^a   Liu, Zhiming ^a   Hazan Halevy, Inbal ^a   Wang, Yongtao ^a   Kantarjian, Hagop M ^a   Priebe, Waldemar ^b   Estrov, Zeev ^a,b  

^a Departments of Leukemia   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; JANUS KINASE 2; JANUS KINASE INHIBITOR; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; STAT PROTEIN; UNCLASSIFIED DRUG; WP 1066;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CASE REPORT; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL STRAIN K 562; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INHIBITION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME DEGRADATION; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL; MALE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION;

ACUTE DISEASE; ADULT; AGED; APOPTOSIS; CASPASES; CELL CYCLE; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; ENZYME INHIBITORS; FEMALE; HUMANS; IMMUNOBLOTTING; JANUS KINASE 2; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN-TYROSINE KINASES; PYRIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED; TYRPHOSTINS;

EID: 37048999580     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0593     Document Type: Article

References (50)

1. Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group Study. Blood 1996;88:2841-51.
2. Sawyers CL. Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer Cell 2002;1:413-5.
3. Rane SG, Reddy EP. Janus kinases: components of multiple signaling pathways. Oncogene 2000;19:5662-79.
4. Peeters P, Raynaud SD, Cools J, et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 1997;90:2535-40.
5. Lacronique V, Boureux Z, Valle VD, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in myeloid leukemia. Science 1997;278:1309-12.
6. Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia-chromosome negative CML and megakaryocytic leukemia. Blood 2005;106:3370-3.
7. Benekli M, Xia Z, Donohue KA, et al. Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood 2002;99:252-7.
8. Min Yh, Eom JI, Cheong JW, et al. Constitutive phosphorylation of AKT/PKB protein in acute myeloid leukemia: its significance as a prognostic variable. Leukemia 2003;17:995-7.
9. Thompson JE. JAK protein kinase inhibitors. Drug News Perspect 2005;18:305-10.
10. 1-S traverse in BALB/c-3T3 cells following either mitogenic stimulation or exogenous expression of E2F-1. Mol Cancer Ther 2004;3:205-13.
11. Levitzki A. Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction. FASEB J 1992;6:3275-82.
12. Levitzki A. Tyrosine kinases as targets for cancer therapy. Eur J Cancer 2002;38:S11-8.
13. Faderl S, Ferrajoli A, Harris D, et al. WP-1034, a novel JAK-STAT inhibitor, with proapoptotic and antileukemic activity in acute myeloid leukemia (AML). Anticancer Res 2005;25:1841-50.
14. Papayannopoulou T, Nakamoto B, Kurachi S, et al. Surface antigen profile and globin phenotype of two new human erythroleukemia lines: characterization and interpretation. Blood 1988;72:1029-38.
15. Wang C, Curtis JE, Minden MD, McCulloch EA. Expression of retinoic acid receptor gene in myeloid leukemia cells. Leukemia 1989;3:236-49.
16. Estrov Z, Cohen A, Gelfand EW, Freedman MH. Synergistic antiproliferative effects on HL-60 cells: deferoxamine enhances cytosine arabinoside, methotrexate, and daunorubicin cytotoxicity. Am J Pediatr Hematol Oncol 1988;10:288-91.
17. Minden MD, Buick RN, McCulloch EA. Separation of blast cells and T lymphocyte progenitors in the blood of patients with acute myeloblastic leukemia. Blood 1979;54:186-95.
18. Ferrajoli A, Talpaz M, Kurzrock Z, et al. Analysis of the effects of tumor necrosis factor inhibitors on human hematopoiesis. Stem Cells 1993;11:112-9.
19. Estrov Z, Manna SK, Harris D, et al. Phenylarsine oxide blocks interleukin-1-induced activation of the nuclear transcription factor NF-κB, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells. Blood 1999;94:2844-53.
20. Thornberry NA, Peterson EP, Ahao JJ, et al. Inactivation of interleukin-1h converting enzyme by peptide (acyloxy)methyl ketones. Biochemistry 1994;33:3934-40.
21. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
22. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 1979;76:4350-4.
23. Gershoni JM, Palade GE. Protein blotting: principles and applications. Anal Biochem 1983;131:1-15.
24. Vermes I , Haanen C, Steffens-Nakken H, Reutelinsperger C. A novel assay for apoptosis: flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein-labelled annexin V. J Immunol Methods 1995;184:39-51.
25. Garcia-Calvo M, Peterson EP, Leiting B, Ruel R, Nicholson DW, Thornberry NA. Inhibition of human caspases by peptide-based and macromolecular inhibitors. J Biol Chem 1998;273:32608-13.
26. Gregoli PA, Bondurant MC. Function of caspases in regulating apoptosis caused by erythropoietin deprivation in erythroid progenitors. J Cell Physiol 1999;178:133-43.
27. Kumar S, Harvey NL. Role of multiple cellular proteases in the execution of programmed cell death. FEBS Lett 1995;375:169-73.
28. Benekli M, Bauer MR, Baumann H, Wetzler M. Signal transducer and activator of transcription proteins in leukemias. Blood 2003;101:2940-54.
29. James C, Ugo V, Le Couedic JP, et al. Unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8.
30. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61.
31. Heim H. The Jak-STAT pathway: cytokine signaling from the receptor to the nucleus. J Recept Signal Transduct Res 1999;19:75-120.
32. Aringer M, Cheng A, Nelson JW, et al. Janus kinases and their role in growth and disease. Life Sci 1999;64:2173-86.
33. Imada K, Leonard WJ. The Jak-STAT pathway. Mol Immunol 2000;37:2-11.
34. Tuyt LML, Bregman K, Lummen C, et al. Differential binding activity of the transcription factor LIL-STAT in immature and differentiated normal and leukemia myeloid cells. Blood 1998;92:1364-73.
35. Garcia R, Jove R. Activation of STAT transcription factors in oncogenic tyrosine kinase signaling. J Biomed Sci 1998;5:79-85.
36. Zong C, Yan R, August A, et al. Unique signal transduction of Erk: constitutive stimulation of the JAKSTAT pathway by an oncogenic receptor-type tyrosine kinase. EMBO J 1996;15:4515-25.
37. Leonard WJ. Role of Jak kinases and STATs in cytokine signal transduction. Int J Hematol 2001;73:271-7.
38. Spiekermann K, Biethahn S, Wilde S, Hiddenmann W, Alves F. Constitutive activation of STAT transcription factors in acute myelogenous leukemia. Eur J Haematol 2001;67:63-71.
39. Iwamura A, Szymanski A, Iwado E, et al. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells in vitro and in vivo. Oncogene 2007;26:2435-44.
40. Zhu H, Shang X, Terada N, Liu C. STAT3 induces antihepatitis Cviral activity in liver cells. Biochem Biophys Res Commun 2004;324:518-28.
41. Kanai M, Konda Y, Nakajima T, et al. Differentiationinducing factor-1 (DIF-1) inhibits STAT3 activity involved in gastric cancer cell proliferation via MEKERK-dependent pathway. Oncogene 2003;22:548-54.
42. Martelli AM, Faenza I, Billi AM, et al. Intracellular 3′-phosphoinositide metabolism and AKT signaling: new mechanisms for tumorigenesis and protection against apoptosis? Cell Signal 2006;18:1101-7.
43. Zhao S, Konopleva M, Cabreira-Hansen M, et al. Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. Leukemia 2004;18:267-75.
44. Shuai K, Halpern J, ten Hoeve J, Rao X, Sawyers CL. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 1996;13:247-54.
45. Chai SK, Nichols GL, Rithman P. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemia patients. J Immunol 1997;159:4720-8.
46. Dai Y, Rahmani M, Pei X-Y, Dent P, Grant S. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. Blood 2004;104:509-18.
47. de Groot RP, Raaijmakers JAM, Lammers J-WJ, Jove R, Koenderman L. STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells. Blood 1999;94:1108-12.
48. Samanta AK, Lin H, Sun T, Kantarjian H, Arlinghaus RB. Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res 2006;66:6468-72.
49. Danial NN, Rothman P. JAK-STAT signaling activated by Abl oncogenes. Oncogene 2000;19:2523-31.
50. Skorski T, Knakaraj P, Nieborowska-Skorska M, et al. Phosphodylinositol-3 kinase activity is regulated by BCR-ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 1995;86:726-36.